# Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

> **NCT05738694** · PHASE3 · RECRUITING · sponsor: **ZHOU FANGJIAN** · enrollment: 298 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Neoadjuvant

## Interventions

- **DRUG:** Axitinib plus Toripalimab
- **PROCEDURE:** nephrectomy

## Key facts

- **NCT ID:** NCT05738694
- **Lead sponsor:** ZHOU FANGJIAN
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738694, "Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05738694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*